Dermatology

This site is intended for healthcare professionals only

Login Register

MD Brand Connect
Webinars
Vaccine Hub
MDTV
Fact Check
Health Dialogues

Medical News & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry
MDTV

This site is intended for healthcare professionals only

Login Register

LoginRegister

Home
Medical news & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry

Susmita Roy

Mpharm (Pharmacology)

Susmita Roy, B pharm, M pharm Pharmacology, graduated from Gurunanak Institute of Pharmaceutical Science and Technology with a bachelor's degree in Pharmacy. She is currently working as an assistant professor at Haldia Institute of Pharmacy in West Bengal. She has been part of Medical Dialogues since March 2021.

Home

Susmita Roy

Articles By : Susmita Roy

NPPA Panel Defers Decision on Separate Price Cap for Cementless Knee Implants

Knee Implant Prices Under Fresh Review: NPPA Weighs 10% Hike Request from Manufacturers

Susmita Roy5 Nov 2025 9:58 PM IST

New Delhi: India's drug pricing regulator, the National Pharmaceutical Pricing Authority (NPPA), is planning to review the ceiling prices of knee...

Abuse of the Process of Law: Delhi HC Upholds Dismissal of Complaint Against Hospital, Doctor Accused of Medical Negligence

Major Relief for SBSF College of Pharmacy: Delhi HC Orders PCI to Evaluate D.Pharm Affiliation

Susmita Roy5 Nov 2025 5:09 PM IST

New Delhi: In a major relief to SBSF College of Pharmacy, the Delhi High Court has directed the Pharmacy Council of India (PCI) to process and decide...

JnJ bags USFDA nod for Akeega plus prednisone for prostate cancer

CDSCO Panel Approves Updated Package Insert for Johnson and Johnson's Stelara

Susmita Roy5 Nov 2025 4:51 PM IST

New Delhi: The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has recommended approval for the updated...

Maharashtra Faces Pharmacy Admission Slump Despite 38 New Colleges, Only 48% Students Confirm Seats

Susmita Roy5 Nov 2025 4:29 PM IST

Mumbai: Maharashtra's Bachelor of Pharmacy (B Pharm) admissions have once again hit a roadblock, with thousands of seats likely to go unfilled this...

CDSCO Panel Flags Ethnic Variability, Seeks More Data from Takeda for Fruquintinib Hard Capsule Approval

CDSCO Panel Approves Updated Package Insert for Takeda's Vedolizumab

Susmita Roy5 Nov 2025 4:16 PM IST

New Delhi: In a key regulatory development, the Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has...

CDSCO Panel Asks Shilpa Biologicals to Revise Phase III Protocol for Recombinant Human Serum Albumin Study

Susmita Roy4 Nov 2025 4:39 PM IST

New Delhi: The Subject Expert Committee (SEC) functioning under the Central Drugs Standard Control Organisation (CDSCO) has sought major revisions in...

Low-Risk Medical Device Makers Get Clarity: CDSCO Publishes Class A Risk Classification List under MDR 2017

Susmita Roy3 Nov 2025 9:07 PM IST

New Delhi: The Central Drugs Standard Control Organisation (CDSCO) has released a detailed Risk Classification List of Class A (non-sterile and...

RML Discontinues MBBS Scholarship Scheme After One Year: Report

PCI Announces Rs 12,400 Monthly Scholarship for GPAT-Qualified M.Pharm Students

Susmita Roy3 Nov 2025 8:22 PM IST

New Delhi: The Pharmacy Council of India (PCI), under the Ministry of Health and Family Welfare, Government of India, has announced the disbursement...

AstraZeneca Gets SEC Nod to Update Lokelma Prescribing Information for Hyperkalemia Treatment

Susmita Roy3 Nov 2025 7:08 PM IST

New Delhi: The Subject Expert Committee (SEC) functioning under the Central Drugs Standard Control Organisation (CDSCO) has recommended approval for...

Jubilant Wins Relief: Allahabad HC Bars Pharma Firms from Using Its Drug Dossier

Susmita Roy2 Nov 2025 2:00 PM IST

New Delhi: In a significant ruling reinforcing copyright protection over pharmaceutical data, the Allahabad High Court has dismissed two appeals filed...

CDSCO Panel Seeks Revised Phase IV Trial Protocol for MSN Labs Nelarabine Injection

MSN Labs Secures SEC Nod for Phase III Trial of Vibegron 75 mg, Excluding Refractory OAB Patients

Susmita Roy2 Nov 2025 12:30 PM IST

New Delhi: The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organization (CDSCO) has approved MSN Laboratories to conduct a...

47 Drug Inspectors for 2.5 Lakh Batches: Kerala Faces Oversight Strain

Nearly 50% of Drug Inspector Posts Vacant at CDSCO, Reveals RTI Response

Susmita Roy1 Nov 2025 10:22 PM IST

New Delhi: Nearly 250 Drug Inspector posts remain vacant across the regulatory and medical device divisions of the Central Drugs Standard Control...

Powered By: Hocalwire

X

We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok